633
Views
37
CrossRef citations to date
0
Altmetric
Inflammatory bowel disease

Klebsiella pneumoniae increases the risk of inflammation and colitis in a murine model of intestinal bowel disease

&
Pages 684-693 | Received 24 Nov 2010, Accepted 01 Feb 2011, Published online: 16 Mar 2011
 

Abstract

Objective. Intrarectal treatment with 2,4,6-trinitrobenzene sulfonic acid (TNBS), an inducer of intestinal inflammation, in mice increases the population size of Enterobacteriaceae, particularly Klebsiella pneumoniae, while reducing the population size of lactic acid bacteria. Therefore, we investigated the effects of these bacteria in TNBS-induced colitis in mice. Material and methods. Colitis was induced in vivo by rectal administration of TNBS in male Institute of Cancer Research mice. Inflammatory markers were determined by enzyme-linked immunosorbent assay and immunoblot analysis. Results. Oral administration of K. pneumoniae increased COX-2, IL-1β, IL-6 and TNF-α expression, NF-κB activation, and lipid peroxidation in the colon, but reduced tight junction-associated proteins, claudin-1, ZO-1 and occludin. K. pneumoniae also deteriorated the expression of inflammatory markers and tight junction-associated proteins in TNBS-induced colitic mice. K. pneumoniae produced β-glucuronidase and lipopolysaccharide, which potently induced NO and COX-2 production in murine peritoneal macrophages. However, oral administration of Lactobacillus johnsonii, which is isolated from the feces of mice, inhibited TNBS-induced colon shortening, the reduction of tight junction-associated proteins, expression of inflammatory markers, and lipid peroxidation. These findings suggest that the disturbance of intestinal bacterial composition, and in particular the irregular increase of K. pneumoniae in the colon, may cause colitis.

Acknowledgment

This work was supported by the Brain Korea 21 Project in 2006.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.